- Israeli Ministry of Health announced that it will begin accepting applications for a medical
cannabis export Pilot Program
- IMC well positioned to leverage German EU-GMP certified subsidiary under the export Pilot
Program to distribute IMC-branded medical cannabis product imports across Europe
TORONTO, CANADA and GLIL YAM, ISRAEL / ACCESSWIRE / October 6, 2020 / IM
Cannabis Corp. (the “Company” or “IMC”) (CSE:IMCC), a multi-country operator (“MCO”) in the
medical cannabis sector with operations in Israel and across Europe, is pleased to announce that the
Israeli Ministry of Health has launched a new pilot program in which medical cannabis producers will
be authorized to export medical cannabis, subject to making certain products available to patients in
Israel at a fixed price of NIS14 per gram (CAD$5.50 per gram) and NIS10 (CAD$4.00 per gram) for
patients over 21 years old and under 21 years old, respectively (the “Pilot Program”). The medical
cannabis products that will be made available under the Pilot Program are at the Company’s discretion.
The Pilot Program is planed for an initial period of three months. IMC-branded products will be
available for immediate application of export permits.
IMC operates in Germany through Adjupharm GmbH (“Adjupharm”), an EU-GMP and EU-GDP
certified medical cannabis distributor. Adjupharm is currently making shipments to its network of ten
distribution partners with IMC-branded products available in pharmacies across Germany. With seven
cultivators currently producing IMC-branded products in Israel, an export market will allow the
Company to bolster the supply of cannabis for its operation in Germany and across Europe, supporting
the rapidly increasing demand in these markets and the Company’s international distribution platform.
Oren Shuster, Chief Executive Officer of IMC commented, “We are very supportive of the Israeli
Ministry of Health’s program to open the market for medical cannabis exports. We have made
tremendous progress establishing our supply and distribution platform for IMC-branded products in both
Israel and Germany. The ability for licensed producers to export from Israel will significantly strengthen
our international supply capabilities as we continue to execute our goal of global leadership for IMCbranded medical cannabis.”
About IM Cannabis Corp.
IMC (CSE: IMCC) is an MCO in the medical cannabis sector headquartered in Israel and with
operations across Europe. Over the past decade, IMC has built its brand as a provider of premium
medical cannabis products in the Israeli market. The Company has also expanded its business to offer
intellectual property related services to the medical cannabis industry based on proprietary processes and
technologies it developed for the production of medical cannabis.
In Europe, IMC operates through a German-based subsidiary and EU-GMP certified medical cannabis
distributor – Adjupharm GmbH. IMC’s European presence is also augmented by strategic alliances with
various pan-European EU-GMP cultivators and distributors with the objective of capitalizing on the
increased demand for medical cannabis products and bringing the IMC brand and its product portfolio to
As one of the world’s medical cannabis pioneers, IMC partners with renowned academic institutions and
scientists as well as allocates resources and investments for the development of innovative technologies
to improve the lives and medical cannabis therapies outcomes of patients around the world.
Disclaimer for Forward-Looking Statements
This press release contains “forward-looking information” and “forward-looking statements” (together,
“forward-looking statements”) within the meaning of applicable Canadian and United States securities
laws. Forward-looking statements are often, but not always, identified by the use of words such as
“seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an
event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar
expressions. Forward-looking information in this press release includes statements relating to the ability
to export IMC-branded product to Germany, the ability of Adjupharm to receive import permits, the
ability of Adjupharm to fulfill its obligations under binding purchase commitments, the Israeli
government granting export permits for IMC-branded products, successful implementation of the Pilot
Program, the expected pricing of medical cannabis under the Pilot Program, the expectation that the
Company will significantly strengthen its international supply capabilities in the event it receives an
export permit from the Israeli Ministry of Health and the Company’s strategic plans.
Forward-looking information is based on assumptions that may prove to be incorrect, including but not
limited to the ability of the Company to execute its business plan, the continued growth of the medical
cannabis market in the countries in which the Company operates or intends to operate, the Company
maintaining “de facto” control over Focus Medical Herbs Ltd. (“Focus Medical”) in accordance with
IFRS 10, Focus Medical in accordance with IFRS 10, Focus Medical maintaining its existing Israeli
cultivation license and the expected decriminalization of cannabis in Israel. The Company considers
these assumptions to be reasonable in the circumstances. However, forward-looking information is
subject to business and economic risks and uncertainties and other factors that could cause actual results
of operations to differ materially from those expressed or implied in the forward-looking information.
Such risks include, without limitation: the ability of the Company to comply with applicable government
regulations in a highly regulated industry; unexpected changes in governmental policies and regulations
affecting the production, distribution, manufacture or use of medical cannabis in Israel, Germany,
Portugal, Greece or any other foreign jurisdictions in which the Company intends to operate; any failure
of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the
Company and Focus Medical having to rely on third party cannabis producers to supply the Company
and Focus Medical with product to successfully fulfill previously announced sales agreements and
purchase commitments; the ability of Focus Medical to deliver on its sales commitments; the risk that
regulatory authorities in Israel may view the Company as the deemed owner of more than 5% of Focus
Medical in contravention to Israeli rules restricting the ownership of Israeli cannabis cultivators and
thereby jeopardizing Focus Medical’s cannabis cultivation license; unexpected disruptions to the
operations and businesses of the Company and/or Focus Medical as a result of the COVID-19 global
pandemic or other disease outbreaks including in the event that Focus Medical were to lose its
designation as an essential service in the State of Israel during the current COVID-19 outbreak; any
unexpected failure of Focus Medical to renew its cultivation license with the Israeli Ministry of Health;
reliance on management; inconsistent public opinion and perception regarding the use of cannabis;
engaging in activities considered illegal under US federal law; failure to meet U.S. stock exchange
listing requirements; failure to obtain effectiveness of a registration statement filed with the U.S.
Securities and Exchange Commission; political instability and conflict in the Middle East; adverse
market conditions; the inherent uncertainty of production and cost estimates and the potential for
unexpected costs and expenses; crop failures; litigation; currency fluctuations; competition; and loss of
key management and/or employees. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements.
For more information:
Chief Executive Officer
SOURCE: IM Cannabis Corp.